Bortezomib before and after high-dose therapy in transplant-eligible patients with newly diagnosed multiple myeloma: Long-term overall survival after more than 10 years of follow-up from the phase III HOVON-65/GMMG-HD4 trial

Elias K. Mai*, Axel Nogai, Henk M. Lokhorst, Bronno van der Holt, Sonja Zweegman, Katja C. Weisel, Sandra Croockewit, Anna Jauch, Jens Hillengass, Marian Stevens-Kroef, Marc S. Raab, Annemiek Broijl, Gerard M.J. Bos, Peter Brossart, Paula Ypma, Christine Hanoun, Uta Bertsch, Thomas Hielscher, Hans J. Salwender, Christoph ScheidHartmut Goldschmidt, Pieter Sonneveld

*Corresponding author for this work

Research output: Contribution to journalComment/Letter to the editorAcademicpeer-review

1 Downloads (Pure)
Original languageEnglish
Article numbere70052
Number of pages5
JournalHemaSphere
Volume8
Issue number11
DOIs
Publication statusPublished - Nov 2024

Cite this